EIKN Stock — Eikon Therapeutics Inc.: Cash, EV, Pipeline

Share price

$8.95

Market cap

$484.8M

Cash

$531.2M

Enterprise value

-$46.4M

Balance sheet

Cash	$531.2M
Debt	$0.0M
Net cash	$531.2M
Enterprise value	-$46.4M
Basic shares	54.1M shares
Fully diluted shares	64.7M shares
Fully diluted market cap	$578.9M
Cash per share	$9.82

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading EIKN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	IMP1734	Phase 2	Advanced Solid Tumor	—
Jan 12 - Feb 23	EIK1004-001 (IMP1707-001)	Phase 2	Advanced Solid Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

EIK1001

Phase 2/3 · Active

Target TLR7/TLR8

Partnerships MSD (clinical trial collaboration and supply agreements for three studies; MSD supplies pembrolizumab at its own cost)

Indications

advanced melanoma (Stage not disclosed)
non-small cell lung cancer (Stage not disclosed)

Status note Phase 2/3 registrational studies of EIK1001 in combination with pembrolizumab in advanced melanoma and NSCLC; company is sponsor of the trials.

EIK1003

Stage not disclosed · Active Modality: selective PARP1 inhibitor

Target PARP1

Partnerships Impact Therapeutics (exclusive license to develop and commercialize selective PARP1 inhibitors including EIK1003 and EIK1004, worldwide excluding China, Hong Kong, Taiwan and Macau)

Indications

not disclosed (Stage not disclosed)

Status note Company product candidate referenced in clinical trials in the 10-Q; phase not stated.

EIK1004

Stage not disclosed · Active Modality: selective PARP1 inhibitor

Target PARP1

Partnerships Impact Therapeutics (exclusive license to develop and commercialize selective PARP1 inhibitors including EIK1003 and EIK1004, worldwide excluding China, Hong Kong, Taiwan and Macau)

Indications

Advanced Solid Tumors (Phase 2)

Status note Company product candidate referenced in clinical trials in the 10-Q; phase not stated.

EIK1005

Phase 1 · Active

Target WRN

Partnerships MSD (clinical trial collaboration and supply agreement for the Phase 1/2 trial; MSD supplies pembrolizumab at its own cost)

Indications

advanced solid tumors (Stage not disclosed)

Status note Phase 1/2 clinical trial in advanced solid tumors in combination with pembrolizumab.

EIK1006

Preclinical · Active

Target androgen receptor

Indications

not disclosed (Stage not disclosed)

Status note Preclinical program; no further details in the current 10-Q excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	IMP1734
Lead indication	Advanced Solid Tumor
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06253130	Phase 2	Recruiting	Sponsor	EIKN	—	Advanced Solid Tumor	—
NCT06907043	Phase 2	Recruiting	Sponsor	EIKN	—	Advanced Solid Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Eikon Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	555,555	no change	0.04%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

EIKN — Eikon Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders